Single Ascending Dose Study of HB2198 in Healthy Participants

NCT07439263 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteer

Interventions

DRUG: HB2198, a Tetravalent Bispecific Anti-CD19/CD20 Antibody with Dual Fc Domains
DRUG: Placebo comparator: HB2198 Diluent

Sponsor

Hinge Bio